OFIX

Business Context and Reporting Period

Company: Orthofix International N.V. (Orthofix)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2001
Business Overview: Orthofix designs, develops, manufactures, and markets medical equipment for the orthopedic market, including external/internal fixation devices, bone growth stimulators, and vascular therapy products. The company operates globally with significant manufacturing and sales in the United States, Italy, the United Kingdom, and the Seychelles.

Key Financial Metrics (Year Ended Dec 31, 2001)

Note: 2000 Net Income included $29.9 million of non-recurring after-tax income from the EBI litigation settlement.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 23% to $162.4 million, driven by 25% growth in North America and 19% growth internationally. Stimulation products grew 26% and vascular products grew 25%.
• Profitability: While operating income increased 34% to $30.5 million, reported Net Income decreased 53% to $21.0 million. This decline is primarily due to the absence of the $29.9 million non-recurring litigation gain recorded in 2000. Excluding non-recurring items, core net income increased 41% year-over-year.
• Cash Flow: Net cash provided by operating activities decreased significantly from $56.3 million in 2000 to $18.9 million in 2001, largely reflecting the one-time litigation proceeds in the prior year. Working capital increased by $15.0 million, driven by higher accounts receivable and tax payments related to the prior year's litigation settlement.
• Capital Structure: Total debt decreased by $5.3 million as the company repaid a $10 million term note. The company repurchased $16.5 million of its own common stock during the year.
• Foreign Exchange: International sales growth was reduced by approximately $1.8 million due to the appreciation of the U.S. dollar against the Euro, U.K. Sterling, and Italian Lira.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Strategic Moves

• Joint Venture: Established a 50/50 joint venture, OrthoRx Inc., with HealthSouth Corporation to provide orthopedic durable medical equipment, investing $3.0 million.
• Capital Expenditures: Planned 2002 capital expenditures are approximately $4.8 million ($3.1M North America, $1.7M International), expected to be funded by operating cash flow.
• Accounting Changes: Adopted SFAS No. 142 effective January 1, 2002, ceasing the amortization of goodwill (previously $3.5 million annually) and moving to an annual impairment test model.

Risks and Contingencies

• Government Inquiry: The company is cooperating with the U.S. Department of Health and Human Services and Department of Defense regarding an inquiry into billing and coding practices for the off-label use of its spinal pulsed electromagnetic field device. No written response has been received, and the outcome is uncertain.
• Legal Proceedings:
  • Kinetic Concepts Inc. (KCI): Ongoing patent infringement litigation regarding the A-V Impulse System; trial not expected before late 2002.
  • Norian Corporation: Patent infringement suit against Stryker (assignee of Orthofix's BoneSource patents); a loss could reduce royalty payments to Orthofix.
  • AME Earnout: Litigation regarding earnout payments to former AME shareholders; Orthofix is vigorously defending.
• Regulatory & Reimbursement: Dependence on third-party payors (Medicare, Medicaid, private insurers) for reimbursement creates risk if policies change or coverage is denied. FDA and foreign regulatory approvals are required for new products.
• Intellectual Property: Reliance on patents and trade secrets; risk of infringement claims or competitors developing non-infringing alternatives.

Investor Verification Checklist

• Core Earnings Quality: Verify the sustainability of the 41% increase in core net income (excluding the 2000 litigation windfall) by reviewing the growth in stimulation and vascular product lines.
• Government Inquiry Status: Monitor the outcome of the U.S. government inquiry regarding off-label billing practices, as a negative resolution could materially impact future revenue and profitability.
• Working Capital Trends: Assess the $15 million increase in working capital investment, specifically the rise in accounts receivable, to ensure collection rates remain healthy.
• Goodwill Impairment: Review the annual goodwill impairment test results under the new SFAS No. 142 standard, given the $56.7 million goodwill balance.
• Foreign Exchange Exposure: Evaluate the impact of currency fluctuations on international margins, as 33% of sales are derived outside the U.S.